All Stories

  1. DuoResp® Spiromax® adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD in Europe (SPRINT)

    Article • Journal of Asthma, July 2019, Taylor & Francis

    Guilherme Safioti

  2. Digital Technologies and Adherence in Respiratory Diseases: The Road Ahead

    Article • European Respiratory Journal, November 2018, European Respiratory Society (ERS)

    Prof Richard W Costello, Guilherme Safioti

  3. Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

    Article • BMC Pulmonary Medicine, June 2018, Springer Science + Business Media

    Professor David Price, Guilherme Safioti

  4. Using Predictive Analytics to Identify Risk of Clinical Asthma Exacerbations

    Article • Journal of Allergy and Clinical Immunology, February 2018, Elsevier

    Guilherme Safioti

  5. Comparison of correct technique and preference for Spiromax®, Easyhaler® and Turbuhaler®: a single-site, single-visit, crossover study in inhaler-naïve adult volunteers

    Article • European Clinical Respiratory Journal, January 2018, Taylor & Francis

    Guilherme Safioti

  6. Independent Identification of Handling Errors for Dry Powder Inhalers, Spiromax® and Turbuhaler®, Using a Delphi Process Involving Respiratory Device Experts

    Article • Pulmonary Therapy, December 2015, Springer Science + Business Media

    Guilherme Safioti

  7. Updated Medication Costs From A Real-Life Cost-Effectiveness Evaluation Of Budesonide/Formoterol Maintenance And Reliever Therapy In Asthma Maintenance And Reliever Therapy In Asthma

    Article • Value in Health, November 2015, Elsevier

    Guilherme Safioti

  8. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler

    Article • International Journal of Pharmaceutics, August 2015, Elsevier

    Guilherme Safioti

  9. Expert Nordic perspectives on the potential of novel inhalers to overcome unmet needs in the management of obstructive lung disease

    Article • European Clinical Respiratory Journal, January 2015, Taylor & Francis

    Guilherme Safioti, Anders Løkke

  10. The Potential Societal Cost Benefits of Improved Inhalation Technique With Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbuhaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in Sw...

    Article • Value in Health, November 2014, Elsevier

    Guilherme Safioti